#esmo22 highlights on first-line atezolizumab in nsclc not eligible for platinum: the ipsos study
Published 2 years ago • 949 plays • Length 2:30Download video MP4
Download video MP3
Similar videos
-
5:32
esmo22 - lba11 ipsos - results 1st-line atezolizumab vs single-agent ct in nsclc not eligible f...
-
5:36
ipsos: 1l atezolizumab vs single-agent chemotherapy in patients with platinum-ineligible nsclc
-
5:18
atezolizumab improves on single-agent chemo for nsclc not eligible for platinum-containing regimen
-
3:35
#esmo22 highlights on actionable inflammatory axis for air pollution induced nsclc
-
3:16
#esmo22 highlights on tils versus ipilimumab in patients with advanced melanoma: the phase 3 study
-
2:22
#esmo22 highlights on neoadj. vs adjuvant pembrolizumab in resected stage iii-iv melanoma:swog s1801
-
2:17
#esmo22 highlights on pembrolizumab with crt in locally advanced hnscc: the keynote-412 study
-
2:37
#esmo22 highlights on abemaciclib nsai in hr /her2- advanced breast cancer: the monarch 3 study
-
2:56
#esmo22 highlights on nirogacestat in patients with progressing desmoid tumours: the defi study
-
1:06
lung cancer highlights from esmo 2022
-
2:59
#esmo21 highlights on atezolizumab combined with folfoxiri bev in 1st-line mcrc: atezotribe study
-
3:27
#esmo21 highlights on patterns of relapse in nsclc to atezolizumab vs bsc after adj ct: impower010
-
3:11
esmo 2020 highlights on pembrolizumab in la-hnscc: the gortec 2015-01 “pembrorad” study
-
2:21
#esmo22 highlights on adt duration with post-operative radiotherapy in prostate cancer: radicals-hd
-
1:21
immunotherapy and targeted treatment for mnsclc | neal ready, md, phd | esmo22 pennsylvania
-
2:56
#esmo22 highlights on cabozantinib with nivo and ipi for intermediate/poor risk adv. rcc: cosmic-313
-
2:26
#esmo21 highlights on pembro chemo in 1st-line metastatic cervical cancer: the keynote-826 study
-
0:36
esmo 2019 daily reporter - editor's picks: lung cancer